Our Team

Our Founders

Stephen Hajduk, PhD

Stephen Hajduk, PhD

Founder & CSO

Extensive scientific track record spanning 47 years with over 100 publications on African Trypanosomes, including pioneering studies on ApoL1 toxicity in these parasites.

Eric DeJesus, PhD

Eric DeJesus, PhD

Founder & CEO

Conceptualized and initially investigated ApoL1 as a therapeutic against human disease in 2010, with proven scientific track record of publications on ApoL1 toxicity.

Michael Cipriano, PhD

Michael Cipriano, PhD

Founder & Vice President R&D

Conceptualized targeting ApoL1 with a bispecific antibody guided system, bringing a strong background in cell biology, bioinformatics, research study design, and data analysis.

Our Scientific Advisors

Brian Longstreet

Brian Longstreet

Business Advisor

CEO and Co-Founder of Exolvo Biosciences; biotech leader with prior leadership roles at Merck and Schering-Plough, driving early-stage innovation.

Ajay L. Nooka, MD MPH

Ajay L. Nooka, MD MPH

Clinical Advisor, Myeloma

Myeloma specialist and clinical research leader at Emory's Winship Cancer Institute, advancing innovative trials for plasma cell disorders.

Gregory B. Lesinski, PhD, MPH

Gregory B. Lesinski, PhD, MPH

Translational Science Advisor, Oncology

Professor and Vice Chair for Basic Research, Department of Hematology and Medical Oncology, and Associate Director for Basic Research at Emory's Winship Cancer Institute advancing immune-oncology and translational cancer research.

Vikas A. Gupta, MD, PhD

Vikas A. Gupta, MD, PhD

Clinical and Translational Science Advisor, Oncology

Vikas Gupta, MD, PhD — Assistant Professor of Hematology and Medical Oncology at Emory University; board-certified hematologist-oncologist advancing myeloma and immunotherapy research.

Serguei V Kozlov, PhD, MBA, PMP

Serguei V Kozlov, PhD, MBA, PMP

Translational Science Advisor, Animal Models

Expert in GEMM-based preclinical oncology, leading translational in vivo model development at Frederick National Lab.